RAD51 and hepatocellular carcinoma: Recently, Samadaei et al. reported that B02, another RAD51 inhibitor, in combination with sorafenib significantly enhanced the efficacy of sorafenib in reducing the cell viability, colony formation ability, and invasion capacity of HCC cells [38].